These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16402084)

  • 1. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics.
    Beitelshees AL; Zineh I; Yarandi HN; Pauly DF; Johnson JA
    Pharmacogenomics J; 2006; 6(3):174-8. PubMed ID: 16402084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
    Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol.
    Liu J; Liu ZQ; Tan ZR; Chen XP; Wang LS; Zhou G; Zhou HH
    Clin Pharmacol Ther; 2003 Oct; 74(4):372-9. PubMed ID: 14534524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.
    Liu J; Liu ZQ; Yu BN; Xu FH; Mo W; Zhou G; Liu YZ; Li Q; Zhou HH
    Clin Pharmacol Ther; 2006 Jul; 80(1):23-32. PubMed ID: 16815314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers.
    Schwartz SG; Puckett BJ; Allen RC; Castillo IG; Leffler CT
    Ophthalmology; 2005 Dec; 112(12):2131-6. PubMed ID: 16325708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population.
    Mahesh Kumar KN; Ramu P; Rajan S; Shewade DG; Balachander J; Adithan C
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):459-66. PubMed ID: 19033826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
    Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
    Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension.
    Beitelshees AL; Zineh I; Yarandi HN; Pauly DF; Johnson JA
    Pharmacotherapy; 2006 Sep; 26(9):1247-54. PubMed ID: 16945046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.
    Magnusson Y; Levin MC; Eggertsen R; Nyström E; Mobini R; Schaufelberger M; Andersson B
    Clin Pharmacol Ther; 2005 Sep; 78(3):221-31. PubMed ID: 16153393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
    Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
    Johnson JA; Zineh I; Puckett BJ; McGorray SP; Yarandi HN; Pauly DF
    Clin Pharmacol Ther; 2003 Jul; 74(1):44-52. PubMed ID: 12844134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
    Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
    Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy.
    Biolo A; Clausell N; Santos KG; Salvaro R; Ashton-Prolla P; Borges A; Rohde LE
    Am J Cardiol; 2008 Sep; 102(6):726-32. PubMed ID: 18773997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac reserve in the transplanted heart: effect of a graft polymorphism in the beta1-adrenoceptor.
    Scharin Täng M; Lindberg E; Grüner Sveälv B; Magnusson Y; Andersson B
    J Heart Lung Transplant; 2007 Sep; 26(9):915-20. PubMed ID: 17845930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy.
    Terra SG; Hamilton KK; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hill JA; Aranda JM; Yarandi HN; Johnson JA
    Pharmacogenet Genomics; 2005 Apr; 15(4):227-34. PubMed ID: 15864115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the Arg389Gly β₁-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment.
    Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Hjelvang BR; Henriksen T; Frandsen E; Forman JL; Torp-Pedersen C; Køber L; Poulsen HE
    Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):779-85. PubMed ID: 22703382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment.
    Suonsyrjä T; Donner K; Hannila-Handelberg T; Fodstad H; Kontula K; Hiltunen TP
    Pharmacogenet Genomics; 2010 May; 20(5):342-5. PubMed ID: 20300048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CAREGENE study: polymorphisms of the beta1-adrenoceptor gene and aerobic power in coronary artery disease.
    Defoor J; Martens K; Zielinska D; Matthijs G; Van Nerum H; Schepers D; Fagard R; Vanhees L
    Eur Heart J; 2006 Apr; 27(7):808-16. PubMed ID: 16421173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applicability of microdialysis as a technique for pharmacokinetic-pharmacodynamic (PK-PD) modeling of antihypertensive beta-blockers.
    Höcht C; DiVerniero C; Opezzo JA; Taira CA
    J Pharmacol Toxicol Methods; 2005; 52(2):244-50. PubMed ID: 16125622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.